NHS.RT rights subscription

NEUBERGER BERMAN HIGH YIELD ST RT (NHS.RT) is allowing beneficial holders of Three rights plus estimated subscription price of 8.07 USD for one new share, (CUSIP 64128C106). Final price will be determined on Expiration DATE.

The terms of the offer are as follows:

Option 1: Take no action [Default option]

Option 2: Exercise rights, Estimated price 8.07 USD/Final price will be determined on expiration date.

Not supporting oversubscribed rights issue.

Minimum Exercise Quantity Requirement: 3 shares or more.

Fractional shares will not be distributed, and round down to the nearest whole number of shares.

Unexercised subscription rights prior to the defined expiration date and time shall be considered invalid. Unless there is an extension of the due date.

The deadline to submit instructions for exercise will be 2023-06-14 16:00 (HONG KONG GMT+8).

Please fill in the following information and use the registered email address of Futu to send an email to cs@futuhk.com.

1. Account Number –
2. Name - (In Chinese or English)
3. Stock code – NHS.RT
4. Options: (1) [Default option] or (2)
5. Number of shares participating in corporate actions –

Note to applicants:
1. If shareholders holding less than 1 shares of NHS.RT, they cannot participate in related corporate actions.
2. Option 1 is the default option. We will help clients to choose option 1 if have not received clients’ emails.
3. Once the relevant application is submitted, the stocks participating in the company's actions cannot be traded and the application cannot be withdrawn.
4. This corporate action does not accept additional applications, the maximum number of applications that a client can apply for does not exceed the number of eligible shares it holds.
5. The pending orders and unsettled shares will not be accepted for the time being.
6. Please confirm that the account funds are sufficient to pay the relevant fees of this corporate action. Otherwise, we will not bear any responsibility for the failure of your application.
7.If there is any update, all the information released by the listed company shall prevail.

Helpful？

Yes No